Focus: Maxion Therapeutics is a UK-based biotechnology company specializing in miniproteins engineered into antibody loops, a novel modality for targeted therapeutics. The company is publicly traded but operates at a relatively early stage with minimal disclosed commercial products.
Profile data last refreshed 22h ago · AI intelligence enriched 2w ago
Stable — net -1 jobs in 30d
0 added, 1 removed. Backfill posture.
Maxion is a high-risk, technology-focused play suited only for scientists betting on miniprotein differentiation; hiring freeze and pipeline opacity make it unsuitable for near-term career progression.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Maxion Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Maxion Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
The histone chaperone SPT2 regulates chromatin structure and function in Metazoa.
Advancements in mammalian display technology for therapeutic antibody development and beyond: current landscape, challenges, and future prospects.
Assessing developability early in the discovery process for novel biologics.
Animal Immunization, in Vitro Display Technologies, and Machine Learning for Antibody Discovery.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo